Gil Blum, an analyst from Needham, reiterated the Buy rating on Autolus Therapeutics (AUTL – Research Report). The associated price target is $8.00.
Geoff Blum has given his Buy rating due to a combination of factors related to Autolus Therapeutics’ progress with its BLA filing for obe-cel in the treatment of adult ALL. The FDA’s acceptance of the filing without the need for an advisory committee meeting, paired with the set PDUFA action date, suggests a streamlined review process. Blum interprets this regulatory milestone as a reduction in the product’s approval risk, which underpins his positive stance on the stock.
Additionally, the anticipation of a submission for EU approval in the first half of 2024 further supports the analyst’s optimistic outlook. The company’s adherence to its prior guidance regarding the BLA filing timeline also adds credibility to its operational execution. These factors collectively contribute to Blum’s decision to reiterate a Buy rating and to raise the price target from $7 to $8, indicating confidence in Autolus Therapeutics’ potential for growth.
In another report released on January 10, Wells Fargo also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Autolus Therapeutics (AUTL) Company Description:
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
- Autolus Therapeutics appoints Azelby to board of directors
- Autolus Therapeutics Announces Changes to its Board of Directors
- Autolus Therapeutics appoints Leiderman to board, Dhingra to step down
- Autolus Therapeutics presents clinical data updates at ASH Annual Meeting 2023
